Quantcast

EAU Position Statement on Screening for Prostate Cancer

April 16, 2009

ARNHEM, The Netherlands, April 16 /PRNewswire/ — The European
Association of Urology (EAU) has taken into consideration the recent
scientific information on randomised screening studies on prostate cancer
(Schröder et al, NEJM 2009). Based on the results of the European Randomised
Study for Screening of Prostate Cancer (ERSPC), the EAU has formulated a
position statement regarding prostate cancer screening in Europe, and the
subsequent actions to be taken by health professionals and health authorities.

In summary, the ERSPC reports on a relative prostate cancer mortality
reduction of at least 20% by PSA-based population screening in 162,000
asymptomatic men aged 55-69 years. For every prostate cancer death prevented,
1410 men have to undergo screening, while 48 are needed to be treated in
excess of the control group population to save one prostate cancer death.
Results of the PLCO (Prostate, Lung, Colon and Ovary) US randomized study of
screening were also published in the same issue of the NEJM (Andriole et al,
NEJM 2009) and to date show no significant effect of screening on mortality
from the disease, but suffered from a significant level of contamination in
the control arm. The study continues.

The EAU adopts the conclusions of the ERSPC study and recognizes the
benefit of screening in terms of mortality reduction, as well as the adverse
effects of overdiagnosis and overtreatment of prostate cancers which could be
quantified for the first time in the setting of a randomized screening study.
Further publication of relevant data is awaited from the ERSPC group in due
course to inform the debate.

For the interest men’s health in Europe and elsewhere, the EAU formulates
the following statements:

    - Prostate cancer is a major health problem, and one of the
    main causes of male cancer deaths. However, current published data are
    insufficient to recommend the adoption of population screening for
    prostate cancer as a public health policy due to the large overtreatment
    effect. Before screening is considered by national health authorities,
    the level of current opportunistic screening, overdiagnosis,
    overtreatment, quality of life, costs, and cost-effectiveness should be
    taken into account.
    - Overdiagnosis of prostate cancer leads potentially to significant
    overtreatment. Health professionals, especially urologists, should avoid
    overtreatment by developing safe methods of cancer
    surveillance/monitoring without invasive therapy. Invasive therapies
    should be tailored to patients' needs and the prognosis of cancers
    diagnosed.
    - Current screening algorithms are insufficient due to a lack of
    specificity and lack of selectivity for aggressive cancers which require
    treatment. The development of novel diagnostic and prognostic markers and
    imaging modalities is needed urgently to enhance the predictive value of
    screening tools.
    - In the absence of population screening, the EAU advises men who
    consider screening by PSA testing and prostate biopsy to obtain
    information on the risks and benefits of screening and individual risk
    assessment.
    - The EAU and the ERSPC study group represent essential European
    stakeholders to further develop health strategies for prostate cancer
    screening.
    - The EAU promotes the quality of care for prostate cancer patients
    in Europe in collaboration with the patient support organization Europa
    Uomo (http://www.europa-uomo.org) through the development of information
    and guidelines.
    - The EAU wishes to support and foster research needed to develop
    reliable active surveillance protocols for low-risk prostate cancers,
    prognostic markers, and targeted therapies in order to deliver optimal
    patient care.

SOURCE European Association of Urology


Source: newswire



comments powered by Disqus